Determining Prognostic Immune Markers in Patients With Ovarian Cancer

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

NCT06611072 ·Status: RECRUITING ·Phase: NA

To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer

NCT06315270 ·Status: NOT_YET_RECRUITING

Study Looking at Biomarkers in Ovarian Cancer

NCT03419689 ·Status: RECRUITING ·Phase: NA

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876 ·Status: COMPLETED ·Phase: PHASE3

A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

NCT02608684 ·Status: COMPLETED ·Phase: PHASE2

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT03410784 ·Status: UNKNOWN ·Phase: PHASE2

Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

NCT01048814 ·Status: COMPLETED

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

NCT04169997 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

NCT03297489 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

NCT00086567 ·Status: COMPLETED

A Cohort Establishment Study of Total Management of Ovarian Cancer

NCT06018935 ·Status: RECRUITING

Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma

NCT06969833 ·Status: RECRUITING ·Phase: NA

Safety of Active Immunotherapy in Subjects With Ovarian Cancer

NCT01456065 ·Status: UNKNOWN ·Phase: PHASE1

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02900560 ·Status: TERMINATED ·Phase: PHASE2

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

NCT03126812 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

NCT05410015 ·Status: RECRUITING

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

NCT03602586 ·Status: COMPLETED ·Phase: PHASE2

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer

NCT03922776 ·Status: TERMINATED ·Phase: NA

Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

NCT01074398 ·Status: UNKNOWN

Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy

NCT07201259 ·Status: NOT_YET_RECRUITING

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00719303 ·Status: UNKNOWN ·Phase: PHASE3

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

NCT03740165 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

NCT02674061 ·Status: COMPLETED ·Phase: PHASE2

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

NCT04375956 ·Status: UNKNOWN ·Phase: PHASE2